Clarenta Group Acquires Leads To Development to Bolster Early-Stage Drug Development Expertise
Clarenta Group announced its majority acquisition of Leads To Development (L2D), a French firm specializing in early-stage drug development. The acquisition enhances Clarenta's capabilities in supporting biotech and pharmaceutical clients from preclinical research through first-in-human clinical trials.
London, UK – October 1, 2026 – Clarenta Group has acquired a majority stake in Leads To Development (L2D), a French organization focused on early-stage drug development. This move significantly strengthens Clarenta's capacity to support biotechnology and pharmaceutical sponsors, extending its services from preclinical strategy to first-in-human clinical trials and beyond.
L2D brings specialized expertise in non-clinical development, manufacturing, and regulatory strategy, which are critical for the initial phases of drug development. Based in Paris, L2D has a history of assisting innovative biotech and pharmaceutical companies by defining development pathways, compiling preclinical evidence, and establishing regulatory strategies to advance new therapies efficiently.
The integration aims to merge L2D's specialized knowledge with Clarenta's existing early development consulting and its Phase I unit. This synergy is intended to strengthen the connection between initial scientific strategy and first-in-human clinical research. Clarenta, which recently launched a new brand identity, positions this acquisition as a key step in its strategy to become a comprehensive early-stage development partner.
L2D will continue to operate as a specialized team from its Paris base, benefiting from Clarenta's broader capabilities. Dr. Chris Smyth, CEO of Clarenta, stated that L2D's addition is crucial for building the company Clarenta envisions, enabling better management of complex development processes for clients from the outset. Christopher Backes of EdgeCap Partners, Clarenta's majority investor, commented that the partnership enhances Clarenta's position in early development, where informed decision-making can yield substantial client value.